{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:59Z","timestamp":1782208259733,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03589-1","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:36:52Z","timestamp":1776847012000},"page":"2996-3013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Overweight and Obesity Landscape in France: Data from the French Cohort of the Multi-country IMPACT-O Study"],"prefix":"10.1007","volume":"43","author":[{"given":"David","family":"Jacobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Artime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"3589_CR1","unstructured":"World Health Organization. Fact sheet, Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight; 2024. Accessed 8 May\u00a02024."},{"key":"3589_CR2","unstructured":"National League Against Obesity. https:\/\/www.obecentre.fr\/wp-content\/uploads\/2024\/07\/Etude-epidemiologique-sur-le-surpoids-et-lobesite-Odoxa-LNCO-OFEO-2024-ConfPresse.pdf; 2024. Accessed 9 Aug 2024."},{"key":"3589_CR3","doi-asserted-by":"publisher","first-page":"14152","DOI":"10.1038\/s41598-021-93432-0","volume":"11","author":"S Czernichow","year":"2021","unstructured":"Czernichow S, Renuy A, Rives-Lange C, et al. Evolution of the prevalence of obesity in the adult population in France, 2013\u20132016: the Constances study. Sci Rep. 2021;11:14152. https:\/\/doi.org\/10.1038\/s41598-021-93432-0.","journal-title":"Sci Rep"},{"key":"3589_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/jcm12030925","volume":"12","author":"A Fontbonne","year":"2023","unstructured":"Fontbonne A, Currie A, Tounian P, et al. Prevalence of overweight and obesity in France: the 2020 Obepi-Roche study by the \u201cLigue Contre l\u2019Ob\u00e9sit\u00e9.\u201d J Clin Med. 2023;12:925. https:\/\/doi.org\/10.3390\/jcm12030925.","journal-title":"J Clin Med"},{"key":"3589_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bl\u00fcher","year":"2019","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288\u201398. https:\/\/doi.org\/10.1038\/s41574-019-0176-8.","journal-title":"Nat Rev Endocrinol"},{"key":"3589_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194831","volume":"13","author":"A-L Feral-Pierssens","year":"2018","unstructured":"Feral-Pierssens A-L, Carette C, Rives-Lange C, et al. Obesity and emergency care in the French CONSTANCES cohort. PLoS ONE. 2018;13:e0194831. https:\/\/doi.org\/10.1371\/journal.pone.0194831.","journal-title":"PLoS ONE"},{"key":"3589_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/oby.23366","volume":"30","author":"AL Feral-Pierssens","year":"2022","unstructured":"Feral-Pierssens AL, Matta J, Rives-Lange C, et al. Health care use by adults with obesity: a French cohort study. Obesity Silver Spring. 2022;30:733\u201342. https:\/\/doi.org\/10.1002\/oby.23366.","journal-title":"Obesity Silver Spring"},{"key":"3589_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-12449-2","volume":"22","author":"J Hecker","year":"2022","unstructured":"Hecker J, Freijer K, Hiligsmann M, Evers SM. Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. BMC Public Health. 2022;22:1\u20133. https:\/\/doi.org\/10.1186\/s12889-021-12449-2.","journal-title":"BMC Public Health"},{"key":"3589_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1159\/000533342","volume":"16","author":"C Fabron","year":"2023","unstructured":"Fabron C, Laville M, Aron-Wisnewsky J, et al. Out-of-pocket expenses in households of people living with obesity in France. Obes Facts. 2023;16:606\u201313. https:\/\/doi.org\/10.1159\/000533342.","journal-title":"Obes Facts"},{"key":"3589_CR10","first-page":"79","volume":"486","author":"\u00c9 Coudin","year":"2016","unstructured":"Coudin \u00c9, Souletie A. Obesity and the labour market: the impacts of corpulence on employment and wages. Econ Stat. 2016;486:79\u2013102.","journal-title":"Econ Stat"},{"key":"3589_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.soin.2016.10.004","volume":"61","author":"M Bernat","year":"2016","unstructured":"Bernat M, Genser L, Oppert JM. Les centres de l\u2019ob\u00e9sit\u00e9 dans la fili\u00e8re de prise en charge de l\u2019ob\u00e9sit\u00e9 s\u00e9v\u00e8re [The place of obesity centres in the treatment of severe obesity]. Soins. 2016;61:26\u20137. https:\/\/doi.org\/10.1016\/j.soin.2016.10.004.","journal-title":"Soins"},{"key":"3589_CR12","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1111\/dom.15845","volume":"26","author":"M Go\u00ebau-Brissonni\u00e8re","year":"2024","unstructured":"Go\u00ebau-Brissonni\u00e8re M, Rives-Lange C, Phan A, et al. Real-life use of liraglutide 3\u00a0mg in obesity management: the SAX-RL study. Diabetes Obes Metab. 2024;26:5488\u201391. https:\/\/doi.org\/10.1111\/dom.15845.","journal-title":"Diabetes Obes Metab"},{"key":"3589_CR13","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Semaglutide WEGOVY 0.25 - 0.5 - 1.0 - 1.7 and 2.4\u00a0mg solution for injection. First assessment. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-05\/wegovy_141222_summary_ct19927.pdf; 2022. Accessed 03 Dec 2024."},{"key":"3589_CR14","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Care pathway guide: overweight and obesity in adults. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-03\/summary_has_care_pathway_guide_overweight_and_obesity_in_adults.pdf; 2024. Accessed 03 Dec 2024."},{"key":"3589_CR15","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Analogues du GLP-1 et ob\u00e9sit\u00e9: nous prenons des mesures pour s\u00e9curiser leur utilisation en France. ANSM. https:\/\/ansm.sante.fr\/actualites\/analogues-du-glp-1-et-obesite-nous-prenons-des-mesures-pour-securiser-leur-utilisation-en-france; 2024. Accessed 28 Nov 2024."},{"key":"3589_CR16","unstructured":"Paitraud D. Management of obesity and overweight: the drug WEGOVY is available in pharmacies. Vidal. https:\/\/www.vidal.fr\/actualites\/31008-prise-en-charge-de-l-obesite-et-du-surpoids-le-medicament-wegovy-est-disponible-en-pharmacie.html; 2024. Accessed 28 Oct 2024."},{"key":"3589_CR17","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Tirzepatide MOUNJARO 2.5 \u2013 5 \u2013 7.5 \u2013 10 \u2013 12.5 and 15\u00a0mg solution for injection in pre-filled pen. Indication extension. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-20761_MOUNJARO_obesite_PIC_EI_AvisDef_CT20761.pdf; 2024. Accessed 10 Dec 2024."},{"key":"3589_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-018-3525-0","volume":"29","author":"PE O\u2019Brien","year":"2019","unstructured":"O\u2019Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29:3\u201314. https:\/\/doi.org\/10.1007\/s11695-018-3525-0.","journal-title":"Obes Surg"},{"key":"3589_CR19","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Ob\u00e9sit\u00e9 de l\u2019adulte: prise en charge de 2e et 3e niveaux. https:\/\/www.has-sante.fr\/jcms\/p_3346001\/fr\/obesite-de-l-adulte-prise-en-charge-de-2e-et-3e-niveaux; 2024. Accessed 03 Dec 2024."},{"key":"3589_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","volume":"10","author":"M Kivim\u00e4ki","year":"2022","unstructured":"Kivim\u00e4ki M, Strandberg T, Pentti J, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10:253\u201363. https:\/\/doi.org\/10.1016\/S2213-8587(22)00033-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3589_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03333-1","author":"E Artime","year":"2025","unstructured":"Artime E, Spaepen E, Zimner-Rapuch S, et al. Epidemiology landscape and impact of overweight and obesity in adults: multi-country results from the IMPACT-O study. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03333-1.","journal-title":"Adv Ther"},{"key":"3589_CR22","unstructured":"EMA. Longitudinal patient data \u2013 France. https:\/\/catalogues.ema.europa.eu\/node\/1059\/administrative-details; 2024. Accessed 6 June 2024."},{"key":"3589_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.03.115","volume":"18","author":"SL Jouaville","year":"2015","unstructured":"Jouaville SL, Miotti H, Coffin G, Sarfati B, Meihoc A. Validity and limitations of the Longitudinal Patient Database France for use in pharmacoepidemiological and pharmacoeconomics studies. Value in Health. 2015;18:A18. https:\/\/doi.org\/10.1016\/j.jval.2015.03.115.","journal-title":"Value in Health"},{"key":"3589_CR24","unstructured":"Weir CB, Jan A. BMI classification percentile and cut off points. Updated 26 June 2023. Treasure Island (FL): StatPearls; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541070\/."},{"key":"3589_CR25","unstructured":"The Book of OHDSI. https:\/\/ohdsi.github.io\/TheBookOfOhdsi\/; 2021. Accesssed 12 Apr 2026."},{"key":"3589_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003584","volume":"18","author":"J Coste","year":"2021","unstructured":"Coste J, Valderas JM, Carcaillon-Bentata L. Estimating and characterizing the burden of multimorbidity in the community: a comprehensive multistep analysis of two large nationwide representative surveys in France. PLoS Med. 2021;18:e1003584. https:\/\/doi.org\/10.1371\/journal.pmed.1003584.","journal-title":"PLoS Med"},{"key":"3589_CR27","unstructured":"Lampropoulou A, Zimner Rapuch S, Artime E, et al. Characteristics of people with overweight or obesity stratified by age, gender, and obesity-related complications: multi-country data from the IMPACT-O Study. European Congress on Obesity. Venice, Italy; 2024."},{"key":"3589_CR28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/dom.13752","volume":"21","author":"ID Caterson","year":"2019","unstructured":"Caterson ID, Alfadda AA, Auerbach P, et al. Gaps to bridge: misalignment between perception, reality and actions in obesity. Diabetes Obes Metab. 2019;21:1914\u201324.","journal-title":"Diabetes Obes Metab"},{"key":"3589_CR29","doi-asserted-by":"crossref","unstructured":"Khare S, Redig J, Tahbaz A, et al. Impact and management of comorbidities in people with obesity: a multinational survey. Poster presented at International Society for Pharmacoeconomics and Outcomes Research \u2013 26th Annual European Congress; Copenhagen, Denmark; 12\u201315 November 2023.","DOI":"10.1016\/j.jval.2023.09.1582"},{"key":"3589_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41366-023-01325-1","volume":"47","author":"M Evans","year":"2023","unstructured":"Evans M, de Courcy J, de Laguiche E, et al. Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey. Int J Obes. 2023;47:750\u20137. https:\/\/doi.org\/10.1038\/s41366-023-01325-1.","journal-title":"Int J Obes"},{"key":"3589_CR31","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.soard.2016.05.010","volume":"12","author":"T Debs","year":"2016","unstructured":"Debs T, Petrucciani N, Kassir R, Iannelli A, Amor IB, Gugenheim J. Trends of bariatric surgery in France during the last 10\u00a0years: analysis of 267,466 procedures from 2005\u20132014. Surg Obes Relat Dis. 2016;12:1602\u20139. https:\/\/doi.org\/10.1016\/j.soard.2016.05.010.","journal-title":"Surg Obes Relat Dis"},{"key":"3589_CR32","first-page":"677","volume":"13","author":"S Halimi","year":"2019","unstructured":"Halimi S. Chirurgie bariatrique: \u00e9tat des lieux en France en 2019. Med Mal Metab. 2019;13:677\u201386.","journal-title":"Med Mal Metab"},{"key":"3589_CR33","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s11695-017-3090-y","volume":"28","author":"F Martini","year":"2018","unstructured":"Martini F, Lazzati A, Fritsch S, Liagre A, Iannelli A, Paolino L. General practitioners and bariatric surgery in France: are they ready to face the challenge? Obes Surg. 2018;28:1754\u20139. https:\/\/doi.org\/10.1007\/s11695-017-3090-y.","journal-title":"Obes Surg"},{"key":"3589_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11690-015-0490-9","volume":"10","author":"A Delcourt","year":"2015","unstructured":"Delcourt A, Andrieux S, Gueorguieva I, et al. Management of the severely obese patient in specialized centers. Obesite. 2015;10:293\u2013305. https:\/\/doi.org\/10.1007\/s11690-015-0490-9.","journal-title":"Obesite"},{"key":"3589_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123519","volume":"13","author":"L Salle","year":"2024","unstructured":"Salle L, Foulatier O, Coupaye M, et al. ACTION-FRANCE: insights into perceptions, attitudes, and barriers to obesity management in France. J Clin Med. 2024;13:3519. https:\/\/doi.org\/10.3390\/jcm13123519.","journal-title":"J Clin Med"},{"key":"3589_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/osp4.518","volume":"7","author":"F Rubino","year":"2021","unstructured":"Rubino F, Logue J, B\u00f8gelund M, et al. Attitudes about the treatment of obesity among healthcare providers involved in the care of obesity-related diseases: a survey across medical specialties in multiple European countries. Obes Sci Pract. 2021;7:659\u201368. https:\/\/doi.org\/10.1002\/osp4.518.","journal-title":"Obes Sci Pract"},{"key":"3589_CR37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41366-024-01514-6","volume":"48","author":"M Kasher Meron","year":"2024","unstructured":"Kasher Meron M, Eizenstein S, Cukierman-Yaffe T, Oieru D. Missed diagnosis\u2014a major barrier to patient access to obesity healthcare in the primary care setting. Int J Obes (Lond). 2024;48:1003\u201310.","journal-title":"Int J Obes (Lond)"},{"key":"3589_CR38","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/oby.22954","volume":"28","author":"EL Ciemins","year":"2020","unstructured":"Ciemins EL, Joshi V, Cuddeback JK, Kushner RF, Horn DB, Garvey WT. Diagnosing obesity as a first step to weight loss: an observational study. Obesity (Silver Spring). 2020;28:2305\u20139.","journal-title":"Obesity (Silver Spring)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03589-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:22:54Z","timestamp":1782206574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3589"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03589-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Esther Artime, Marine Bertrand and Aya Kayali are employees and minor shareholders of Eli Lilly and Company. Anastasia Lampropoulou is a former employee and a former minor shareholder of Eli Lilly and Company. David Jacobi has received consulting fees from Eli Lilly and Company, Novo Nordisk and Fitforme, payment or honoraria from Eli Lilly and Company, Novo Nordisk and Amgen and received travel reimbursement from Eli Lilly and Company and Novo Nordisk. Atif Adam has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All analyses performed in this study were conducted in accordance with Data Use Agreement terms as specified by the data owners. Reference made to the France LPD is intended to be descriptive of the data asset licensed by IQVIA. For the France database, there was no institutional review board applicable to the usage and dissemination of the results of this study or required registration of the protocol with additional ethics oversight. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}